CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 15,400 shares, a growth of 6.2% from the October 15th total of 14,500 shares. Based on an average trading volume of 11,100 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.2% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CLGN shares. EF Hutton Acquisition Co. I raised CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a report on Wednesday, August 21st.

Institutional Investors Weigh In On CollPlant Biotechnologies

Institutional investors have recently added to or reduced their stakes in the stock. Villere ST Denis J & Co. LLC raised its holdings in shares of CollPlant Biotechnologies by 24.4% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after buying an additional 95,000 shares in the last quarter. Pinnacle Associates Ltd. increased its holdings in CollPlant Biotechnologies by 6.4% during the 2nd quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock valued at $2,805,000 after purchasing an additional 33,905 shares in the last quarter. Finally, Benjamin Edwards Inc. acquired a new stake in CollPlant Biotechnologies during the 3rd quarter valued at $112,000. 21.69% of the stock is owned by institutional investors and hedge funds.

CollPlant Biotechnologies Price Performance

Shares of NASDAQ CLGN traded up $0.05 during trading hours on Tuesday, hitting $4.20. 2,570 shares of the stock were exchanged, compared to its average volume of 10,166. CollPlant Biotechnologies has a one year low of $3.61 and a one year high of $6.99. The company’s 50 day moving average is $4.40 and its 200 day moving average is $4.93.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Tuesday, August 20th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). CollPlant Biotechnologies had a negative return on equity of 65.98% and a negative net margin of 2,535.70%. The company had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.70 million. On average, sell-side analysts predict that CollPlant Biotechnologies will post -1.44 EPS for the current year.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.